Law360, New York (April 06, 2009, 12:00 AM ET) -- Two bills have been introduced in the House that aim to create an FDA approval process for follow-on biologics similar to that established for generic drugs in the Hatch-Waxman Act of 1984.
The first bill, H.R. 1427, the “Promoting Innovation and Access to Life-Saving Medicine Act”, outlines an approval process that is highly favorable to follow-on biologic companies, whereas the second bill, H.R. 1548, the “Pathway for Biosimilars Act”, stakes out a position somewhat more favorable to the innovator biologics industry. A new law could take...
Biologics Legislation In The 111th Congress
To view the full article, take a free trial now.
